Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

PARP1 and PARP2 dual inhibitors, such as olaparib, have been recently FDA approved for the treatment of advanced breast and ovarian cancers. However, their effects on bone mass and bone metastasis are unknown. Here we show that olaparib increases breast cancer bone metastasis through PARP2, but not PARP1, specifically in the myeloid lineage, but not in the cancer cells. Olaparib treatment or PARP1/2 deletion promotes osteoclast differentiation and bone loss. Intriguingly, myeloid deletion of PARP2, but not PARP1, increases the population of immature myeloid cells in bone marrow, and impairs the expression of chemokines such as CCL3 through enhancing the transcriptional repression by β-catenin. Compromised CCL3 production in turn creates an immune-suppressive milieu by altering T cell subpopulations. Our findings warrant careful examination of current PARP inhibitors on bone metastasis and bone loss, and suggest cotreatment with CCL3, β-catenin inhibitors, anti-RANKL or bisphosphonates as potential combination therapy for PARP inhibitors.


Hao Zuo, Dengbao Yang, Qiwen Yang, Haidong Tang, Yang-Xin Fu, Yihong Wan. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nature communications. 2020 Mar 27;11(1):1578

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32221289

View Full Text